藍思科技(300433.SZ):孫公司擬86.66億元投建精密部件生產項目及改擴建項目
格隆匯4月23日丨藍思科技(300433.SZ)公佈,公司全資孫公司泰州藍思為進一步優化產品和銷售結構、提高市場份額,擬以自有資金和銀行借款的方式投資建設“精密部件生產項目及改擴建項目”。本項目預計總投資86.66億元,項目全部建成達產後預計新增消費類電子產品合金機殼3300萬件/年,電子產品鋁合金機殼背蓋組裝件3200萬件/年,電子產品模具、檢治具65400套/年,電子產品刀具728.4萬片/年,汽車及新能源金屬結構件7500萬件/年。
本項目全部建成投產後,預計可實現年銷售收入80億元,利潤總額4.21億元,税後靜態投資回收期為10.97年,税後財務內部收益率為8.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.